Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus
Clinical Physiology and Functional Imaging · 2024-01 · 44 (1) · 112-117
DOI: 10.1111/cpf.12857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Physiology and Functional Imaging, online erschienen am 27.10.2023. Verfasst von Michele Correale und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ospedali Riuniti University Hospital, Foggia, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Background
SGLT2 inhibitors have been shown to reduce hospitalisation in patients with chronic heart failure (CHF). The cardioprotective mechanisms of gliflozins however have not been fully elucidated. The aim of this study was therefore to evaluate the effect of SGLT2 inhibitors on right and left ventricular function in patients with diabetes and HF.
Methods
Seventy‐eight patients with diabetes and CHF were enroled in the study and followed up; 38 started treatment with SGLT2i, while the remaining 40 continued their previous antidiabetic therapy. All patients underwent conventional, TDI and strain echocardiography in an ambulatory setting, at the beginning and after 3 months of therapy with SGLT2i.
Results
After 3 months of therapy with SGLT2i, echocardiographic parameters assessing both left and right ventricular dimensions and function were found as significantly improved in patients switching to SGLT2i than control group: LVEF (45 ± 9% vs. 40 ± 8%, p < 0.001), LVEDD (54 ± 6.5 vs. 56 ± 6.5 mm, p < 0.01), GLS (−13 ± 4% vs. −10 ± 3%, p < 0.001), TAPSE (21 ± 3 vs. 19 ± 3 mm, p < 0.001), RV S' (12.9 ± 2.5 vs 11.0 ± 1.9 cm/sec, p < 0.001) and PAsP (24 ± 8 vs. 31 ± 9 mmHg, p < 0.001). Also mitral (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) and tricuspid regurgitation (1.0 ± 0.5 vs. 1.3 ± 0.5, p < 0.01) improved after SGLT2i therapy. Changes were not statistically significant in patients not treated with SGLT2i (p n.s. in all cases).
Conclusions
In a real‐world scenario, treatment with SGLT2i in patients with CHF and diabetes is associated with an improvement in both left and right ventricular function assessed at echocardiography. These data may explain potential anti‐remodelling effects of gliflozins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ospedali Riuniti University Hospital, Foggia, Italy.
- Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Zitieren
APA
Correale, M., Mazzeo, P., Fortunato, M., Paradiso, M., Furore, A., Fanizzi, A. I., Tricarico, L., Pastore, G., Alfieri, S., Brunetti, N. D., & Lamacchia, O. (2024). Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus. Clinical Physiology and Functional Imaging, 44(1), 112-117. https://doi.org/10.1111/cpf.12857
Vancouver
Correale M, Mazzeo P, Fortunato M, Paradiso M, Furore A, Fanizzi AI, et al. Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus. Clinical Physiology and Functional Imaging. 2024;44(1):112-117. doi:10.1111/cpf.12857
BibTeX
@article{Correale2024,
author = {Correale, Michele and Mazzeo, Pietro and Fortunato, Martino and Paradiso, Matteo and Furore, Andrea and Fanizzi, Angela I and Tricarico, Lucia and Pastore, Giuseppe and Alfieri, Simona and Brunetti, Natale D and Lamacchia, Olga},
title = {Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus},
journal = {Clinical Physiology and Functional Imaging},
year = {2024},
volume = {44},
number = {1},
pages = {112--117},
doi = {10.1111/cpf.12857}
}
EUVIMED